

Supporting Information for

SARS-CoV-2 in wastewater settled solids is associated with COVID-19 cases in a large urban sewershed

Katherine E. Graham^{1*}, Stephanie K. Loeb^{1*}, Marlene K. Wolfe^{1*}, David Catoe², Nasa Sinnott-Armstrong³, Sooyeol Kim¹, Kevan M. Yamahara⁴, Lauren M. Sassoubre⁵, Lorelay M. Mendoza¹, Laura Roldan-Hernandez¹, Linlin Li⁸, Krista R. Wigginton^{7#}, Alexandria B. Boehm^{1#}

1. Department of Civil & Environmental Engineering, Stanford University, 473 Via Ortega, Stanford, CA, USA, 94305

2. Joint Initiative for Metrology in Biology, SLAC National Accelerator Laboratory, Stanford, CA, USA, 94305

3. Department of Genetics, Stanford University School of Medicine, Stanford, CA
Emmett Interdisciplinary Program in Environment and Resources, Stanford University, Stanford, CA

4. Monterey Bay Aquarium Research Institute, Moss Landing, CA, USA, 95039,

5. Department of Engineering, University of San Francisco, San Francisco, CA, USA, 94117

7. Department of Civil & Environmental Engineering, University of Michigan, Ann Arbor, MI, USA, 48109

8. County of Santa Clara Public Health Department, San Jose, California

* These authors contributed equally to this work.

Corresponding authors:

Alexandria Boehm, 650-724-9128, aboehm@stanford.edu

Krista Wigginton, (734) 763-2125, kwigg@umich.edu

Number of pages: 23

Number of Figures: 8

Number of Tables: 6

36 **Materials and Methods**

37 **Sample collection.** POTW A had thin sludge in their primary sedimentation tank that averaged
38 about 900-1400 mg/L TSS when measured with a field probe. To obtain thicker sludge samples,
39 operators collected 1000 mL of primary sludge at 8:00 each day, waited for the solids to settle
40 (approximately 10 min), and decanted liquid to provide 40 mL of concentrated primary settled
41 solids. The date assigned to a 24-hour composite sample is the date on which the majority of
42 the sample was collected.

43 **Storage conditions of samples.** Method evaluation samples: For POTW A, influent samples
44 were stored at -20°C until analysis while solids samples were stored at -20°C for up to 3 days
45 and subsequently transferred to -80°C until analysis. Samples from POTW B were initially
46 stored at 4°C (median storage 9 d) and then transferred to storage at -20°C (influent) and -80°C
47 (solids) until analysis. Although immediate storage at -80°C is preferred, logistical constraints
48 and public health orders during the pandemic required initial refrigeration for samples from
49 POTW B. Longitudinal solids samples from POTW B were stored as described for the method
50 evaluation samples except median storage time at 4°C prior to being frozen was 4 days.

51

52 **Influent PEG concentration and nucleic-acid extraction methods.** Prior to beginning the
53 PEG concentration procedure, 100 µl of $\sim 10^7$ cp/ml MHV strain A59 concentrate was spiked into
54 the clarified influent as a recovery standard. MHV is an enveloped beta coronavirus; it was
55 cultured, concentrated, and purified as described elsewhere^{1,2}. The MHV-spiked influent was
56 equilibrated on ice for 30 minutes. An aliquot was then immediately placed into a Qiagen
57 AllPrep PowerViral DNA/RNA extraction kit and nucleic acids were extracted and processed by
58 reverse-transcription quantitative polymerase chain reaction (RT-QPCR) for PMMoV and MHV
59 (methods below) to determine concentrations prior to the viral concentration procedure.
60 Subsequently, PEG8000 (MilliporeSigma, Burlington, MA) and NaCl were to the sample at final
61 concentrations of 8 g/100mL and 0.2 M, respectively. The sample was then shaken, and then
62 incubated overnight at 4°C. The following day, samples were centrifuged for 30 minutes at
63 20,000xg. 30 mL of the supernatant was discarded, and then the pellet was washed from the
64 side of the tube with the remaining supernatant and the samples were then centrifuged for
65 another 30 minutes at 20,000xg. The remaining supernatant was aspirated, and the virus-
66 containing pellet was suspended in 200 µl of PBS and stored at -80°C until further processing
67 (within 3 days).

68 The concentrated influent was then thawed and spiked with 75 µl of $\sim 10^7$ copies/ml attenuated
69 bovine coronavirus (BCoV) vaccine (Calf-Guard, Zoetis) as an extraction positive control. The
70 attenuated BCoV was shipped lyophilized and resuspended in 3 mL of RNase/DNase-free water
71 and stored at 4°C. The resuspended BCoV stock was quantified by first extracting nucleic acids
72 from 0.2 mL with a Qiagen AllPrep PowerViral DNA/RNA kit and then quantifying with RT-
73 QPCR (methods below). Nucleic acids from concentrated influent samples were also extracted
74 with the PowerViral DNA/RNA extraction kit following manufacturer's directions with two
75 modifications: 1) in step 8, 200 µl of solution IRS was added to samples to increase inhibitor
76 removal, and 2) in step 16, water was added to the spin column, incubated for 5 minutes, and

77 then nucleic acids were eluted from the column. The final volume of the extract was 50 μ L. An
78 extraction blank (negative control) was included in each batch of sample extraction.

79
80 **Additional details on solids processing.** The exact mass of each aliquot of solids was
81 recorded. Solids aliquoted for powerfecal extraction were then spiked with 5 μ L of $\sim 10^7$ copies/ml
82 attenuated BCoV suspension, while solids aliquoted for RNeasy extraction were spiked with 20
83 μ L of the BCoV suspension. Samples were mixed and allowed to equilibrate on ice for 1 hour.
84 Two biological replicates were completed per sample (2 powerfecal and 2 RNeasy extractions
85 per POTW per time point). To obtain RNA, nucleic acids were extracted according to the
86 manufacturer protocol. The eluted volume of RNA from the two kits was 60 μ L (powerfecal) and
87 100 μ L (RNeasy). Extraction blanks were run with each sample batch.

88
89 **Reverse transcription prior to QPCR.** The RNA was reverse transcribed to cDNA using iScript
90 cDNA synthesis kit (cat.no.: 1708890; Biorad, Hercules, CA) with random hexamers following
91 manufacturer's instructions. The 20 μ L reactions consisted of 10 μ L of RNA template, 4 μ L of
92 iScript reaction mix, 1 μ L of iScript reverse transcriptase mix, and 4 μ L of DNase/RNase-free
93 water. NTCs for the RT step consisted of the iScript RT master mix with 15 μ L of RNase/DNase-
94 free water.

95 **Generation of cDNA standards.** cDNA standards for N1, N2, MHV and BCoV assays were
96 generated using TopTaq Master Mix Kit for End-Point PCR following the recommended protocol
97 with 2 μ L cDNA template and an annealing temperature gradient from 54-64°C. The template
98 for N1 and N2 consisted of plasmids from IDT containing sequences for the SARS-CoV-2
99 targets, the template for BCoV was a direct extraction of the vaccine strain, and the template for
100 MHV was a direct extraction from a concentrated solution of cultured MHV. PCR products were
101 identified using gel electrophoresis in 1X TAE for 40 mins at 100 V and bands were excised and
102 purified using a QIAquick Gel Extraction Kit. The mass of cDNA was then determined using a
103 Qubit fluorometer dsDNA kit. Standards were diluted into 30 x 30 μ L aliquots at concentrations
104 of 10^6 cp/5 μ L and stored at -80°C. Standards were thawed and diluted into the standard curve
105 concentrations immediately prior to use. PMMoV standards were DNA ultramers from IDT and
106 were diluted in DNase/RNase-free water to a final concentration of 2.8×10^6 gc/ μ L. NTCs in
107 duplicate were included on each plate.

108 **QPCR assays.** SARS-CoV-2 N1 and N2 qPCR assays were run in a 20 μ L reaction using
109 TaqPath qPCR Master Mix with 0.5 μ M of each forward and reverse primer (IDT), 0.125 μ M of
110 the probe (IDT), 5 μ L cDNA template, and 0.625 mg/mL bovine serum albumin. Thermocycling
111 conditions consisted of a 2 min denature at 95°C, followed by 45 cycles of denaturing for 3 s at
112 95°C and annealing for 30 s at 55°C. BCoV assay was run in a 20 μ L reaction using iTaq
113 Supermix, 0.5 μ M of each forward and reverse primer, 0.125 μ M of the probe, 0.625 mg/mL
114 BSA, and 5 μ L cDNA template. Thermocycling conditions consisted of a 10 min denature at
115 95°C, followed by 45 cycles of denaturing for 15 s at 95°C, annealing for 30 s at 60°C and an
116 extension for 1 min at 60°C. MHV assay was run in a 20 μ L reaction using TaqPath qPCR
117 Master Mix with 0.5 μ M of each forward and reverse primer, 0.125 μ M of the probe, 5 μ L cDNA
118 template, and 0.625 mg/mL bovine serum albumin. Thermocycling conditions consisted of a 2

119 min denature at 95°C, followed by 45 cycles of denaturing for 3 s at 95°C and annealing for 30 s
120 at 57°C. PMMoV assay was run in a 25 µL reaction using Environmental 2.0 Master Mix with
121 0.4 µM of each forward and reverse primer, 0.125 µM of the probe, and 2 µL cDNA template.
122 Thermocycling conditions consisted of a 10 min activation at 95°C, followed by 45 cycles of
123 denaturing for 15 s at 95°C and annealing for 1 min at 60°C.

124 **ddRT-PCR assays.** For method evaluation experiments, ddPCR SARS CoV-2 BioRad kit triplex
125 assay was run according to the kit instructions using a 20 µL reaction with One-Step RT-ddPCR
126 Advanced Kit for Probes Supermix, 15 mM DTT, 1X primer/probe assay mix, and 5 µL RNA
127 template. Final concentrations of the primers and probes were 900 nM and 250 nM,
128 respectively. Thermocycling conditions consisted of 60 min RT at 50°C and 10 min enzyme
129 activation at 95°C, followed by 40 cycles of 30 s denaturing at 94°C, and 30 s of annealing at
130 55°C, and a 10 min enzyme deactivation step at 98°C and 30 mins droplet stabilization at 4°C.
131 After stabilization, droplets were immediately transferred to the droplet reader, or stored
132 overnight at 4°C and enumerated using the plate reader the following day.

133 When transitioning from method optimization to running longitudinal samples for POTW B, we
134 developed a duplex assay with only N1 and N2 targets (no human RNase P (RP) target). The
135 duplex assay for N1 and N2 for the longitudinal samples was run according to the same
136 parameters listed above. A duplex assay targeting BCoV and PMMoV was also developed to
137 calculate the recovery and fecal strength of each sample, respectively. For that assay, each well
138 was a 20 µL reaction with One-Step RT-ddPCR Advanced Kit for Probes Supermix, 15 mM
139 DTT, 1X primer/probe assay mix, and 5 µL RNA template. Final concentrations of the primers
140 and probes were 900 nM and 250 nM, respectively. Thermocycling conditions consisted of 60
141 min RT at 50°C and 10 min enzyme activation at 95°C, followed by 40 cycles of 30 s denaturing
142 at 94°C, and 30 s of annealing at 55°C, and a 10 min enzyme deactivation step at 98°C and 30
143 mins droplet stabilization at 4°C. After stabilization, droplets were immediately transferred to the
144 droplet reader, or stored overnight at 4°C and enumerated using the plate reader the following
145 day.

146 **2-step ddRT-PCR.** RT was performed as described above for QPCR using the iScript cDNA
147 synthesis kit from undiluted, 1:10 diluted, and 1:50 diluted RNA from solids samples. The
148 undiluted samples were also diluted 1:10 again before ddPCR to assess any difference in
149 inhibition. The generated cDNA was then used as template for a ddPCR simplex assay for the
150 SARS CoV-2 N1 target using the ddPCR supermix for probes with the same primer-probe
151 concentrations and thermocycling conditions specified in the BioRad SARS-CoV-2 Droplet
152 Digital PCR kit. Positive and negative controls were used as described above, and the same
153 criteria as described above were used for threshold setting, positive scoring, and minimum
154 droplet generation.

155 **ddRT-PCR data analysis.** During data analysis for method optimization experiments, clusters
156 were assigned manually as described in the BioRad SARS-CoV-2 ddPCR Test Kit Instructions
157 For Use. Samples were analyzed as duplicate merged wells, and the number of droplets
158 generated exceeding 10,000 for all samples except one (7107 droplets), and with the average
159 number of droplets generated being 15,000+. The fluorescence separation for the single

160 positive N1 cluster appeared above 1200 AU (Channel 1), separating from the negative cluster
161 by >6000 AU. The fluorescence separation for the single positive RP cluster appeared to the
162 right of 7000 AU (channel 2), separating from the negative cluster by >2000 AU. The single
163 positive N2 cluster was a 1:1 mix of channel 1 and 2 fluorophores, it appeared above 7000 AU
164 and overlapping or to the right of 5000 AU. Clusters containing dual positive targets were rare
165 outside of the positive control, but were assigned when present with separation from the single
166 clusters >500 AU. Representative example cluster data for an environmental sample, positive
167 control, and negative control, is shown in Figure S8. All NTCs were negative for SARS CoV-2
168 N1 and N2, although the occasional 1-2 positive RP droplets were identified in NTC samples.
169 Note that we did not use the RP results in our study. Three positive droplets per target were
170 required for a sample to be positive for that target.

171

172

173 For the longitudinal data which was generated using the duplex assays, we manually
174 thresholded the droplets in QuantaSoft Analysis Pro. Representative data from an
175 environmental sample, a positive control, and a negative control is shown in Figure S8. For
176 longitudinal data, the average number of accepted droplets was 37,666 (range: 15,913-59,813)
177 for the N1/N2 duplex assay. The average copies per partition (λ) was 2.6×10^{-4} (range: 0-
178 3.3×10^{-3}). For the BCoV/PMMoV assay, the average number of accepted droplets was
179 29,911 (range: 14,345-45,333) and the average copies per partition was 0.0168 (range: 0-
180 0.986). Recovery of BCoV and PMMoV concentrations are shown in Figure S7. All NTCs and
181 extraction blanks were negative. Interplate variability was assessed by comparing
182 concentrations of the positive control wells on each plate.

183

184 See Table S6 for the reporting table from the dMIQE guidelines.

185

186

187

188

189

190

191

192 Table S1: Assay primers, probes, and conditions for all PCR assays.
 193

Amplicon	Forward Primer	Reverse Primer	Starting Position	Ending Position	Size (# bases)	Probe Sequence	Probe Location
SARS CoV-2_N1	GAC CCC AAA ATC AGC GAA AT	TCT GGT TAC TGC CAG TTG AAT CTG	28287	28358	72	FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1	28309- 28332
SARS CoV-2_N2	TTA CAA ACA TTG GCC GCA AA	GCG CGA CAT TCC GAA GAA	29164	29230	67	FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1	29188- 29210
BCoV	CTGGAAG TTGGTGG AGTT	ATTATCG GCCTAA CATACAT C	29026	29110	85	CCTTCATA TCTATACA CATCAAGT TGTT	29058- 29085
PMMoV	GAGTGGT TTGACCTT AACGTTT GA	TTGTCTG GTTGCA ATGCAA GT	1878	1945	68	FAM- CCTACCG AAGCAAAT G-MGB- NFQ	1906- 1921
MHV	CACGCAG CTCGAAA GAAATG	GGATTA GATATC ATCCAC CTCTA	28690	28961	272	TAATGAAG AAATGAGA CTGCCCC TA	28913- 28937

194

195

196 Table S2. Summary of QPCR assay efficiencies and R² of standard curve regression. Ranges
197 are reported for all the plates ran for the project

Assay Target	Efficiency Range	R² Range
SARS CoV-2 N1	89.6 - 98.5	0.998 - 1
SARS CoV-2 N2	88.1 - 96.2	0.996 - 1
BCoV	81.3 - 96.0	0.996 - 0.997
MHV	87.6 - 105.0	0.984 - 0.998
PMMoV	77.8 - 96.3	0.990 - 0.999

198

199 Table S3. RT-QPCR results for N1 and N2 SARS-CoV-2 targets. For influent, a “1” indicates a
 200 positive including BLOQ and “0” a negative. For solids, the number of biological replicates with
 201 at least one technical replicate positive is indicated (0, 1, or 2). The detected target is given in
 202 parentheses adjacent to the number. A blank cell indicates that the particular sample type was
 203 not run on that date.

Date	Influent POTW A (Palo Alto)	Solids POTW A (PowerFecal)	Influent POTW B (San Jose)	Solids POTW B (PowerFecal)	Solids POTW B (RNeasy)
3.22.20	0	0	0	1 (N1)	1 (N1)
3.23.20			0	1 (N1)	
3.25.20	0	0	1 (N2)	1 (N1)	1 (N1), 1 (N2)
3.29.20	0	0	0	0	2 (N1)
3.30.20			0	1 (N1)	
4.1.20	0	0	0	0	1 (N1)
4.15.20	0	1 (N1)	0	0	0

204
 205

206
 207
 208
 209
 210

Table S4. ddRT-PCR results for N1 and N2 SARS-CoV-2 targets. For influent, a “0” indicates not detected, the concentration measured in copies/ml are provided for positive samples. For solids, the number of biological replicates positive is indicated (0, 1, or 2). The detected target is given in parentheses adjacent to the number. Solids concentrations are provided in Figure 1.

Date	Influent POTW A (Palo Alto)	Sludge POTW A (PowerFecal)	Influent POTW B (San Jose)	Sludge POTW B (PowerFecal)	Sludge POTW B (RNeasy)
3.22.20	0	0	0	1 (N1) 2 (N2)	2 (N1, N2)
3.23.20			0	1 (N1, N2)	
3.25.20	10.9 (N1)	0	0	2 (N1, N2)	2 (N1, N2)
3.29.20	0	0	5.5 (N1)	2 (N1, N2)	2 (N1, N2)
3.30.20			0.5 (N2)	1 (N2)	
4.1.20	0	0	6.4 (N1)	2 (N1, N2)	2 (N1, N2)
4.15.20	0	0	5.8 (N1)	1 (N1) 2 (N2)	1 (N1, N2)

211
 212

213

214 Table S5: Theoretical detection limits for N1 and N2 assays. Units are cp/g wet weight for solids
 215 and cp/ml for influent. Cells are blank if that dilution was not run.

Extraction Method		2 step RT-qPCR (assuming 1 cp/ rxn)	1 step RT-ddPCR (assuming 3 cp/ 2 merged wells)	1 step RT-ddPCR (assuming 3 cp/ 3 merged wells)
PowerFecal	Undiluted	53	60	
	1:10 Dilution	530	600	
	1:50 Dilution	2700		
Rneasy	Undiluted	11	12	8
	1:10 Dilution	110	120	80
	1:50 Dilution	530		
Influent - PowerViral	Undiluted	0.5	0.4	
	1:10 dilution	5	4	

216

217

218

219 Table S6: Average and standard deviations (SD) of ΔCq for different dilutions of RNA for solids
 220 samples. Samples were extracted with either the Qiagen AllPrep PowerFecal RNA extraction kit
 221 or the RNeasy PowerSoil RNA extraction kit. Samples were considered uninhibited if the ΔCq
 222 for 1:10 dilutions were 2.3-4.3, as a 1:10 dilution with a 100% efficient assay would yield a ΔCq
 223 of 3.3. Samples were considered uninhibited if the ΔCq for 1:5 dilutions were 1.3-3.3, as a 1:5
 224 dilution with a 100% efficient assay would yield a ΔCq of 2.3. Whereas results from POTW A
 225 suggest inhibition was alleviated by diluting 1:10, results indicate inhibition potentially remained
 226 for POTW B.

227 *indicates sample types that showed inhibition, on average

		PMMoV ΔCq		BCoV ΔCq	
		Average	SD	Average	SD
POTW A Power Fecal	1:10 - Undiluted	1.30*	0.65	2.85	0.68
	1:50 - 1:10	1.48	1.35	2.03*	0.91
POTW B Power Fecal	1:10 - Undiluted	-2.89*	1.15	0.73*	1.11
	1:50 - 1:10	-0.84*	0.89	-0.57*	0.88
POTW B RNeasy	1:10 - Undiluted	-1.87*	0.51	-0.44*	0.93
	1:50 - 1:10	-0.97*	0.76	-0.70*	1.02

228

229

230

231 Table S7: Details for essential and desired information as requested in the updated dMIQE
 232 guidelines³. Figure S8 provides example experimental results as suggested to report in section
 233 9 of the table.


ITEM TO CHECK	PROVIDED	COMMENT
	Y/N	
1. SPECIMEN		
Detailed description of specimen type and numbers	Y	included in methods section
Sampling procedure (including time to storage)	Y	included in methods section
Sample aliquotation, storage conditions and duration	Y	included in methods section
2. NUCLEIC ACID EXTRACTION		
Description of extraction method including amount of sample processed	Y	included in SI
Volume of solvent used to elute/resuspend extract	Y	included in SI
Number of extraction replicates	Y	included in SI
Extraction blanks included?	Y	included in methods section
3. NUCLEIC ACID ASSESSMENT AND STORAGE		
Method to evaluate quality of nucleic acids	N	not done
Method to evaluate quantity of nucleic acids (including molecular weight and calculations when using mass)	N	NA
Storage conditions: temperature, concentration, duration, buffer, aliquots	Y	included in methods section and SI
Clear description of dilution steps used to prepare working DNA solution	Y	included in methods section and SI
4. NUCLEIC ACID MODIFICATION		
Template modification (digestion, sonication, pre-amplification, bisulphite etc.)	N	NA
Details of repurification following modification if performed	Y	Zymo kit included in SI
5. REVERSE TRANSCRIPTION		
cDNA priming method and concentration	Y	included in SI
One or two step protocol (include reaction details for two step)	Y	included in methods section and SI
Amount of RNA added per reaction	Y	included in SI
Detailed reaction components and conditions	Y	included in SI
Estimated copies measured with and without addition of RT*	N	not done
Manufacturer of reagents used with catalogue and lot numbers	Y	included in SI
Storage of cDNA: temperature, concentration, duration, buffer and aliquots	Y	included in methods section
6. dPCR OLIGONUCLEOTIDES DESIGN AND TARGET INFORMATION		
Sequence accession number or official gene symbol	Y	included in SI
Method (software) used for design and <i>in silico</i> verification	N	NA
Location of amplicon	Y	in table S1
Amplicon length	Y	in table S1
Primer and probe sequences (or amplicon context sequence)**	Y	in table S1
Location and identity of any modifications	N	NA
Manufacturer of oligonucleotides	Y	included in SI
7. dPCR PROTOCOL		
Manufacturer of dPCR instrument and instrument model	Y	included in methods section
Buffer/kit manufacturer with catalogue and lot number	Y	included in methods section
Primer and probe concentration	Y	included in SI
Pre-reaction volume and composition (incl. amount of template and if restriction enzyme added)	Y	included in SI
Template treatment (initial heating or chemical denaturation)	N	NA
Polymerase identity and concentration, Mg ⁺⁺ and dNTP concentrations***	N	NA
Complete thermocycling parameters	Y	included in SI
8. ASSAY VALIDATION		
Details of optimisation performed	Y	details of optimization performed in methods section and SI
Analytical specificity (vs. related sequences) and limit of blank (LoB)	N	we did not perform an experiment to examine the LoB
Analytical sensitivity/LoD and how this was evaluated	Y	included in methods section and SI- we determined a theoretically lowest concentration detected
Testing for inhibitors (from biological matrix/extraction)	Y	included in methods section, in figures, and in SI
9. DATA ANALYSIS		
Description of dPCR experimental design	Y	included in methods section and SI
Comprehensive details negative and positive of controls (whether applied for QC or for estimation of error)	Y	included in methods and SI
Partition classification method (thresholding)	Y	included in methods section
Examples of positive and negative experimental results (including fluorescence plots in supplemental material)	Y	included in SI figures
Description of technical replication	Y	included in methods section and SI
Repeatability (intra-experiment variation)	Y	description of error included in methods section
Reproducibility (inter-experiment/user/lab etc. variation)	Y	included in methods section and SI
Number of partitions measured (average and standard deviation)	Y	included in SI
Partition volume	N	did not estimate
Copies per partition (λ or equivalent) (average and standard deviation)	Y	included in SI
dPCR analysis program (source, version)	Y	included in methods section and SI
Description of normalisation method	N	NA
Statistical methods used for analysis	Y	included in methods section and SI
Data transparency	able on request:	raw data available upon request

234

235

236 Table S8. Please see included excel file with results from statistical models.


237



239

240 Figure S1: Comparison of recovery of spiked SARS-CoV-2 RNA from PEG precipitation and
 241 ultrafiltration methods to concentrate influent samples. Biological replicates of one sample were
 242 concentrated using PEG precipitation and ultrafiltration, and SARS-CoV-2 RNA (from a high titer
 243 clinical case) was spiked into nucleic acid extracts. Spiked extracts were then RTed as either
 244 undiluted extracts or 1:10 dilutions in DNase/RNase-free water. The cDNA was then quantified
 245 using qPCR: the 1:10 diluted extracts that were RTed were run as undiluted cDNA, and the
 246 undiluted extracts that were RTed were run either undiluted or as 1:10 dilutions during qPCR.
 247 Dilutions of the samples presented have already been accounted for by multiplying by the
 248 dilution factor. Direct comparisons between PEG and ultrafiltration data revealed similar results
 249 for both methods, and that diluting RNA before reverse transcription increased the recovery
 250 more than diluting cDNA before qPCR, suggesting that inhibition in RT step affected recovery
 251 more than inhibition in the qPCR step. Error bars represent standard deviations of technical
 252 qPCR replicates (n=2). The influent sample tested here came from a wastewater treatment
 253 plant located on Stanford Campus (Codiga Resource Recovery Center); this influent would
 254 normally be delivered to POTW A.


255




256
257
258
259

Figure S2: Representative QPCR standard curves for each assay used during methods optimization experiments for influent and solids.


260
261



262



263




264

265 Figure S3. RT-QPCR results for endogenous (PMMoV) and exogenous (BCoV and MHV)
266 recovery targets at different dilutions to test for inhibition. Top row: PMMoV, BCoV, and MHV
267 recoveries from influent at both POTW A and B with undiluted extracts, extracts diluted 1:10
268 prior to the RT step, and cDNA products diluted 1:10 prior to qPCR. Middle row: recoveries of
269 PMMoV and BCoV from solids collected at both POTW A and B and extracted with powerfecal
270 kit. Extracts were measured undiluted and diluted 1:10 and 1:50 prior to the RT step. Bottom
271 row: recoveries of PMMoV and BCoV from solids collected at POTW B with Rneasy kit. Extracts
272 were measured undiluted and diluted 1:10 and 1:50 prior to the RT step. The empty symbols
273 represent measurements below detection limits. Error bars represent standard deviation.

274

275



276

277


278 Figure S4: Mean concentrations of qPCR technical replicates of PMMoV in concentrated
279 influent samples (left y-axis); Mean recoveries of MHV and BCoV spike-in surrogates (using
280 qPCR technical replicates) (right y-axis). Measured by two-step RT-qPCR; MHV was spiked into
281 samples before concentrating and recovery was calculated by dividing concentrations in
282 concentrated influent by concentrations of unconcentrated influent (a subsample taken after the
283 MHV was spiked). BCoV was spiked into samples after concentration, but prior to nucleic acid
284 extraction and recovery was calculated by dividing by the theoretical concentration of BCoV
285 spiked into each sample, based on the concentration and volume of BCoV stock spiked. No
286 data available for POTW A for 3/23 and 3/30. Error bars on concentrations of MHV and PMMoV
287 represent the standard deviations of technical qPCR replicates (n=2). Due to constraints on the
288 availability of RNA template, the BCoV assay was not tested on samples diluted 1:10 before the
289 RT step.

290

291


292

293
294
295




296

297 Figure S5. N1, N2, PMMoV, and recovery of BCoV in solids from POTW B in each biological
298 replicate using data from the RNeasy kit. N1 and N2 data were obtained using digital RT-PCR in
299 the undiluted template unless the 1:10 diluted template produced a concentration higher than
300 the upper confidence bound on the undiluted template concentration; PMMoV and BCoV
301 recovery data were generated using RT-QPCR. The dilution of RT-QPCR template producing
302 the largest PMMoV concentration or BCoV recovery was used. Errors on RT-QPCR data are
303 standard deviations of technical replicates. Errors on ddRT-PCR data are total errors as
304 standard deviations. Each measurement is labeled with the POTW identifier (B) followed by the
305 date, followed by the biological replicate number (1 or 2). Error bars are not discernible from the
306 symbol in some cases.



307
 308 Figure S6. N1, N2, PMMoV, and recovery of BCoV in solids from POTW A and B in each
 309 biological replicate using data from the powerfecal kit. N1 and N2 data were obtained using
 310 digital RT-PCR using undiluted template; PMMoV and BCoV recovery data were generated
 311 using RT-QPCR. The dilution of RT-QPCR template producing the largest PMMoV
 312 concentration or BCoV recovery was used. Errors on RT-QPCR data are standard deviations of
 313 technical replicates. Errors on ddRT-PCR data are total errors as standard deviations. Each
 314 measurement is labeled with the POTW identifier (A or B) followed by the date, followed by the
 315 biological replicate number (1 or 2). Error bars are not discernible from the symbol in some
 316 cases.

318



319

320 Figure S7. Recovery of BCoV and PMMoV concentrations for the longitudinal samples. Error
 321 bars represent the standard deviation as represented by the total error from the ddPCR
 322 machine; they are difficult to see as they are often smaller than the symbol.

323

324


325

326


327

328


329




330



331



332



333

334

335

336

337

338

Figure S8: Examples of ddRT-PCR experimental results for a no template control (left facet plots), a representative sample (middle facet plots), and a positive control containing SARS-CoV-2 RNA isolated from clinical samples (N1 and N2- top two rows) or PCR standards (BCoV and PMMoV- bottom two rows) (right facet plots). The top two rows are 2D heat plots, with color

339 representing the density of droplets in each cluster, with red being a higher density and blue
340 representing a single droplet occupying that space. 2D heat plots were created with twoddPCR
341 ⁴. Negative droplets occur in the bottom left corner for all samples; there are many negative
342 droplets, resulting in the red cluster at Ch1 amplitude ~ 5000-7700, Ch2 amplitude ~ 2550-5000,
343 in each plot for the triplex assay (top row) and cluster at Ch1 amplitude ~ 800-1400, Ch2
344 amplitude ~ 900-1250 in each plot for the duplex assay (middle row). Positive droplets are the
345 blue, green, and yellow clusters in the environmental sample and positive control plots (middle
346 and right panels) at Ch1 amplitude > 7700, Ch2 amplitude > 5000 for the triplex assay and Ch1
347 amplitude >1400, Ch2 amplitude > 1250 for the duplex assay. The bottom two rows are 1D plots
348 of results using the BCoV/PMMoV duplex assay. Colored droplets above the band of grey
349 negative droplets were considered positive droplets. 1D plots were exported from QuantaSoft
350 Analysis Pro (BioRad). All plates were manually thresholded in QuantaSoft Analysis Pro. NTCs
351 had at most 1-2 positive droplets for targets N1, N2, RP, BCoV, or PMMoV.
352
353
354

355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371

References

- (1) Ye, Y.; Ellenberg, R. M.; Graham, K. E.; Wigginton, K. R. Survivability, Partitioning, and Recovery of Enveloped Viruses in Untreated Municipal Wastewater. *Environ. Sci. Technol.* **2016**, *50* (10), 5077–5085. <https://doi.org/10.1021/acs.est.6b00876>.
- (2) Rockey, N.; Arts, P. J.; Li, L.; Harrison, K. R.; Langenfeld, K.; Fitzsimmons, W. J.; Lauring, A. S.; Love, N. G.; Kaye, K. S.; Raskin, L.; Roberts, W. W.; Hegarty, B.; Wigginton, K. R. Humidity and Deposition Solution Play a Critical Role in Virus Inactivation by Heat Treatment on N95 Respirators. *medRxiv* **2020**, 2020.06.22.20137448. <https://doi.org/10.1101/2020.06.22.20137448>.
- (3) The dMIQE Group; Huggett, J. F. The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020. *Clinical Chemistry* **2020**, *66* (8), 1012–1029. <https://doi.org/10.1093/clinchem/hvaa125>.
- (4) Chiu, A.; Ayub, M.; Dive, C.; Brady, G.; Miller, C. J. Twoddpcr: An R/Bioconductor Package and Shiny App for Droplet Digital PCR Analysis. *Bioinformatics* **2017**, *33* (17), 2743–2745. <https://doi.org/10.1093/bioinformatics/btx308>.